LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article: Role of prostate stem cell antigen in prostate cancer research.

    Jalkut, Mark W / Reiter, Robert E

    Current opinion in urology

    2002  Volume 12, Issue 5, Page(s) 401–406

    Abstract: Purpose of review: The identification of cell surface antigens is critical to the development of future prognostic and therapeutic modalities for the treatment of prostate cancer. Several prostate-specific proteins have been identified and are under ... ...

    Abstract Purpose of review: The identification of cell surface antigens is critical to the development of future prognostic and therapeutic modalities for the treatment of prostate cancer. Several prostate-specific proteins have been identified and are under investigation. This review reports on prostate stem cell antigen (PSCA), a protein with restricted expression that may have prognostic and therapeutic utility.
    Recent findings: PSCA is a glycosylphosphatidylinositol-anchored cell-surface protein belonging to the Ly-6/Thy-1 family of cell surface antigens, and a murine homologue has been described. It is expressed in the normal human prostate and overexpressed in human prostate cancers. Its overexpression has been correlated with increased Gleason score, advanced stage and bone metastasis. PSCA is co-amplified with MYC, an independent predictor of progression and death. PSCA may therefore be a useful predictor of tumor biology and a useful target of immunotherapy against prostate cancer. Evidence suggests a potential role in strategies employing cytotoxic T cell lymphocytes. Anti-tumor activity has been demonstrated with monoclonal antibodies in tumor take and established tumor xenograft models. Conjugated antibody has recently been reported to have anti-tumor activity in preclinical models.
    Summary: PSCA may serve as a tool in refining the prognosis of an individual cancer and may be a useful therapeutic target for immunotherapy. Future studies will be required to confirm its clinical utility as a prognostic factor. Future animal and clinical studies will be required to test various immunotherapy strategies for safety and efficacy. The study of PSCA regulation and expression may provide information on normal prostate development and prostate carcinogenesis.
    MeSH term(s) Antigens, Neoplasm ; Biomedical Research ; GPI-Linked Proteins ; Humans ; Male ; Membrane Glycoproteins/genetics ; Membrane Glycoproteins/therapeutic use ; Neoplasm Proteins/genetics ; Neoplasm Proteins/therapeutic use ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/therapy
    Chemical Substances Antigens, Neoplasm ; GPI-Linked Proteins ; Membrane Glycoproteins ; Neoplasm Proteins ; PSCA protein, human
    Language English
    Publishing date 2002-08-09
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1091792-5
    ISSN 1473-6586 ; 0963-0643
    ISSN (online) 1473-6586
    ISSN 0963-0643
    DOI 10.1097/00042307-200209000-00006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.

    Chamie, Karim / Chang, Sam S / Kramolowsky, Eugene / Gonzalgo, Mark L / Agarwal, Piyush Kumar / Bassett, Jeffrey C / Bjurlin, Marc / Cher, Michael L / Clark, William / Cowan, Barrett E / David, Richard / Goldfischer, Evan / Guru, Khurshid / Jalkut, Mark W / Kaffenberger, Samuel D / Kaminetsky, Jed / Katz, Aaron E / Koo, Alec S / Sexton, Wade J /
    Tikhonenkov, Sergei N / Trabulsi, Edouard J / Trainer, Andrew F / Spilman, Patricia / Huang, Megan / Bhar, Paul / Taha, Sharif A / Sender, Lennie / Reddy, Sandeep / Soon-Shiong, Patrick

    NEJM evidence

    2022  Volume 2, Issue 1, Page(s) EVIDoa2200167

    Abstract: IL-15 Superagonist NAI in BCG-Unresponsive NMIBCIn this trial, patients with BCG-unresponsive bladder CIS with or without Ta/T1 papillary disease or BCG-unresponsive high-grade Ta/T1 papillary NMIBC were treated with intravesical NAI, an IL-15 ... ...

    Abstract IL-15 Superagonist NAI in BCG-Unresponsive NMIBCIn this trial, patients with BCG-unresponsive bladder CIS with or without Ta/T1 papillary disease or BCG-unresponsive high-grade Ta/T1 papillary NMIBC were treated with intravesical NAI, an IL-15 superagonist, plus BCG. Primary end points were CR at 3 or 6 months for patients with CIS disease and DFS rate at 12 months for those with high-grade Ta/T1 disease. CR rate was 71% (58 of 82 patients), and the DFS rate was 55.4%.
    MeSH term(s) Humans ; BCG Vaccine ; Non-Muscle Invasive Bladder Neoplasms ; Interleukin-15 ; Urinary Bladder Neoplasms/therapy
    Chemical Substances BCG Vaccine ; Interleukin-15
    Language English
    Publishing date 2022-11-10
    Publishing country United States
    Document type Journal Article
    ISSN 2766-5526
    ISSN (online) 2766-5526
    DOI 10.1056/EVIDoa2200167
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top